Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med. 2021 12; 9(12):1349-1351.

View in: PubMed